[Intravitreal triamcinolone acetonide injections in treatment of cystoid macular edema due to diabetic maculopathy].
OBJECTIVE
To appoint the most adequate follow-up parameter of intravitreal TA injections in CME treatment due to diabetic maculopathy and to find the most reliable treatment scheme.


METHODS
4 mg (in 0.1 ml) of crystalline TA were injected into the vitreous of 17 eyes.


RESULTS
There was a statistically significant improvement of BCVA for distance and near vision. There was statistically significant difference in retinal thickness outcomes measured at baseline and at the end of thefollow-up by both OCT and RTA No correlation of BCVA changes and retinal thickness changes measured in OCT and RTA was found.


CONCLUSIONS
Intravitreal TA administration seems to be an effective method of treatment in diabetic CME. OCT is the most adequate method of follow-up of intravitreal TA injections in treatment of CME due to diabetic maculopathy. RTA and FA changes analysis are alternative monitoring methods. Dosage of 4mg TA in 0.1 ml seems to be sufficient. In cases of CME recurrence subsequent intravitreal injection in the first 6 month after initial injection seems to unnecessary.
Lubczyńska
Anna
A
Katedry i Kliniki Okulistyki Akademii Medycznej w Poznaniu.
Kociecki
Jarosław
J
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D003930:Diabetic Retinopathy / Q000150:complications*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000473:pathology*; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*
D000893:Anti-Inflammatory Agents; D014222:Triamcinolone Acetonide